• Policy
• It takes 218 days to register after applying for a new drug
• by Kim, Jung-Ju Oct 31, 2022 06:07am

• InterView
• “BMS makes the next leap with its solid pipeline”
• by Eo, Yun-Ho Oct 31, 2022 06:06am

• Company
• MET-targeted anticancer drug Tabrecta reattempts reimb
• by Eo, Yun-Ho Oct 31, 2022 06:06am

• Policy
• Koselugo & Retevmo's benefit registration can be shortened
• by Lee, Tak-Sun Oct 31, 2022 06:06am

• Company
• Samsung Biologics surpassed ₩2 trillion in sales
• by Kim, Jin-Gu Oct 31, 2022 06:06am

• Company
• The commercialization of Camzyos is expected in Korea
• by Eo, Yun-Ho Oct 28, 2022 05:57am

• Company
• Zerbaxa's benefit in 5 Years
• by Oct 28, 2022 05:57am

• Opinion
• [Reporter’s View]Raising price of cold medicines not enough
• by Lee, Tak-Sun Oct 28, 2022 05:56am

• Company
• AZ-Abbott to copromote diabetic kidney disease treatments
• by Eo, Yun-Ho Oct 28, 2022 05:56am

• Company
• Vaccine Development in 100 Days of Pandemic
• by Oct 28, 2022 05:55am